Table 3. Multivariate analysis for the association between clinical characteristics and survival in metastatic PDAC patients.
| Variables | Category | n | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR | 95% CI | P value | |||
| PLR | ≤123 | 57 | 1 | ||
| >123 | 77 | 1.721 | 1.162–2.550 | 0.007** | |
| Age | – | 1 | |||
| Increasing | 0.993 | 0.971–1.016 | 0.564 | ||
| Gender | Male | 89 | 1 | ||
| Female | 45 | 0.616 | 0.413–0.918 | 0.017* | |
| KPS | 90 | 111 | 1 | ||
| 80 | 19 | 1.073 | 0.365–3.152 | 0.898 | |
| 70 | 4 | 1.082 | 0.641–1.825 | 0.769 | |
| Location | Head | 44 | 1 | ||
| Body/tail | 90 | 1.438 | 0.945–2.188 | 0.090 | |
| Chemotherapy | Monotherapy | 42 | 1 | ||
| Combined therapy | 92 | 0.588 | 0.388–0.890 | 0.012* | |
The multivariate Cox regression model adjusted for gender, KPS, location, and WBC, platelets, hemoglobin. *, P<0.05; **, P<0.01. PDAC, pancreatic ductal adenocarcinoma; HR, hazards ratio; PLR, platelet to lymphocyte ratio; KPS, Karnofsky Performance Status.